Victory Capital Management Inc. Sells 930 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Victory Capital Management Inc. cut its position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 1.9% in the second quarter, HoldingsChannel reports. The firm owned 47,160 shares of the company’s stock after selling 930 shares during the period. Victory Capital Management Inc.’s holdings in Tyra Biosciences were worth $754,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. RA Capital Management L.P. raised its position in Tyra Biosciences by 43.9% during the 1st quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock valued at $170,832,000 after purchasing an additional 3,180,155 shares in the last quarter. BVF Inc. IL raised its position in Tyra Biosciences by 70.1% during the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock valued at $76,444,000 after purchasing an additional 1,921,599 shares in the last quarter. Vanguard Group Inc. raised its position in Tyra Biosciences by 18.6% during the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock valued at $14,757,000 after purchasing an additional 140,833 shares in the last quarter. Kynam Capital Management LP raised its position in shares of Tyra Biosciences by 51.4% in the 1st quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock worth $8,449,000 after acquiring an additional 175,000 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Tyra Biosciences by 8.8% during the 4th quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock worth $1,419,000 after purchasing an additional 8,324 shares during the last quarter. 84.14% of the stock is owned by institutional investors.

Insider Activity at Tyra Biosciences

In related news, CEO Todd Harris sold 5,698 shares of the stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $24.31, for a total value of $138,518.38. Following the completion of the transaction, the chief executive officer now directly owns 1,496,729 shares of the company’s stock, valued at approximately $36,385,481.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 15.40% of the stock is currently owned by insiders.

Tyra Biosciences Stock Performance

NASDAQ:TYRA opened at $24.36 on Friday. The stock has a market capitalization of $1.28 billion, a P/E ratio of -14.50 and a beta of 1.01. The company’s 50-day simple moving average is $21.29 and its 200-day simple moving average is $18.72. Tyra Biosciences, Inc. has a fifty-two week low of $10.38 and a fifty-two week high of $25.14.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.09. On average, research analysts forecast that Tyra Biosciences, Inc. will post -1.53 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on TYRA shares. HC Wainwright reiterated a “buy” rating and issued a $23.00 target price on shares of Tyra Biosciences in a report on Wednesday, July 3rd. Piper Sandler began coverage on shares of Tyra Biosciences in a report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price target on the stock. Oppenheimer raised their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Wedbush restated an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a report on Thursday, August 8th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Tyra Biosciences currently has an average rating of “Moderate Buy” and an average target price of $26.40.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.